MoonLake Immunotherapeutics (MLTX.O), a developer of an antibody-derived treatment for inflammatory skin conditions, is working with an investment bank and having early-stage conversations with drugmakers interested in a potential acquisition.
Related stories
Exclusives | Europe
Read more
Berlin considers full Uniper exit, targets deal after summer
13 January 2025
Exclusives | Europe
Read more
Shein IPO: UK regulator decision slowed by NGO challenge
12 December 2024
Exclusives | Europe
Read more